Raltegravir in the prevention of mother-to-child transmission of HIV-1: Effective transplacental transfer and delayed plasma clearance observed in preterm neonates

AIDS

Volumn 26, Issue 18, 2012, Pages 2421-2423

  Hegazi, Aseel ^a   Mc Keown, Denise ^b   Doerholt, Katja ^a   Donaghy, Sheila ^a   Sadiq, Syed T ^a,b   Hay, Phillip ^a,b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTEGRASE INHIBITOR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

ADULT; CASE REPORT; DELIVERY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; NEWBORN; NONHUMAN; PATIENT COMPLIANCE; PLACENTA PREVIA; PLACENTAL TRANSFER; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SMALL FOR DATE INFANT; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; PYRROLIDINONES;

EID: 84870171093     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835a9aeb     Document Type: Letter

References (10)

1. Taha TET, Dallabetta GA, Canner JK, Chiphangwi JD, Liomba G, Hoover DR, et al. The effect of human immunodeficiency virus infection on birthweight, and infant and child mortality in urban Malawi. Int J Epidemiol 1995;24:1022-1029. (Pubitemid 26434296)
2. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484.
3. Besunder J, Reed M, Blumer J. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokineticpharmacodynamic interface (Part I). Clin Pharmacokinet 1988;14:189.
4. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JVR, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatmentnaive patients with HIV-1 infection: a multicentre, doubleblind randomised controlled trial. Lancet 2009;374:796-806.
5. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46:125.
6. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor. J Clin Pharmacol 2011;51:1376-1402.
7. Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 2010;65:2050.
8. Mckeown DA, Rosenvinge M, Donaghy S, Sharland M, Holt DW, Cormack I, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010;24:2416.
9. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999;13:479.
10. Hirt D, Ekouevi DK, Pruvost A, Urien S, Arrive E, Blanche S, et al. Plasma and Intracellular Tenofovir Pharmacokinetics in the Neonate (ANRS 12109 Trial, Step 2). Antimicrobial Agents and Chemotherapy 2011;55:2961.